loxoprofen has been researched along with Disease Models, Animal in 10 studies
loxoprofen: RN given refers to parent cpd without isomeric designation; structure in first source
loxoprofen : A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-[(2-oxocyclopentyl)methyl]phenyl group. A prodrug that is rapidly converted into its active trans-alcohol metabolite following oral administration.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Spinal stenosis was induced by placing two pieces of silicon rubber strips in the lumbar (L4 and L6) epidural space of rats." | 5.32 | Effects of orally administered OP-1206 alpha-CD with loxoprofen-Na on walking dysfunction in the rat neuropathic intermittent claudication model. ( Akimaru, S; Ito, H; Katsube, N; Maegawa, H; Marsala, M; Nakai, K; Takenobu, Y; Takimizu, H, 2003) |
| "Knee pain was assessed by weight distribution on the hind paw, and cartilage damage and MMP production in the joints were evaluated 18 days after surgery." | 1.36 | High molecular weight hyaluronic acid relieved joint pain and prevented the progression of cartilage degeneration in a rabbit osteoarthritis model after onset of arthritis. ( Hashizume, M; Koike, N; Mihara, M; Suzuki, M; Yoshida, H, 2010) |
| "Omeprazole (100 mg/kg) was given p." | 1.36 | Protective effect of lafutidine, a histamine H2 receptor antagonist, against loxoprofen-induced small intestinal lesions in rats. ( Amagase, K; Kato, S; Ochi, A; Sugihara, T; Takeuchi, K, 2010) |
| "Spinal stenosis was induced by placing two pieces of silicon rubber strips in the lumbar (L4 and L6) epidural space of rats." | 1.32 | Effects of orally administered OP-1206 alpha-CD with loxoprofen-Na on walking dysfunction in the rat neuropathic intermittent claudication model. ( Akimaru, S; Ito, H; Katsube, N; Maegawa, H; Marsala, M; Nakai, K; Takenobu, Y; Takimizu, H, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Zhang, D | 1 |
| Bian, Q | 1 |
| Li, J | 1 |
| Huang, Q | 1 |
| Gao, J | 1 |
| Fukumoto, A | 1 |
| Tajima, K | 1 |
| Hori, M | 1 |
| Toda, Y | 1 |
| Kaku, S | 1 |
| Matsumoto, H | 1 |
| Yamamoto, T | 1 |
| Kaku, M | 1 |
| Sumi, H | 1 |
| Yashima, Y | 1 |
| Izumino, J | 1 |
| Tanimoto, K | 1 |
| Shioyama, R | 1 |
| Aoki, Y | 1 |
| Ito, H | 2 |
| Matsuta, Y | 1 |
| Nagase, K | 1 |
| Oyama, N | 1 |
| Miwa, Y | 1 |
| Akino, H | 1 |
| Imamura, Y | 1 |
| Yokoyama, O | 1 |
| Hashizume, M | 1 |
| Koike, N | 1 |
| Yoshida, H | 1 |
| Suzuki, M | 1 |
| Mihara, M | 1 |
| Amagase, K | 2 |
| Ochi, A | 2 |
| Sugihara, T | 1 |
| Kato, S | 1 |
| Takeuchi, K | 2 |
| Kojo, A | 1 |
| Mizunoe, A | 1 |
| Taue, M | 1 |
| Kinoshita, N | 1 |
| Nakamura, E | 1 |
| Nakai, K | 1 |
| Takenobu, Y | 1 |
| Takimizu, H | 1 |
| Akimaru, S | 1 |
| Maegawa, H | 1 |
| Marsala, M | 1 |
| Katsube, N | 1 |
1 review available for loxoprofen and Disease Models, Animal
| Article | Year |
|---|---|
New therapeutic strategy for amino acid medicine: prophylactic and healing promoting effect of monosodium glutamate against NSAID-induced enteropathy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Food Additives; Gene Expre | 2012 |
9 other studies available for loxoprofen and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Enhancing effect of fumaric acid on transdermal penetration of loxoprofen sodium.
Topics: Administration, Cutaneous; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Disease Mo | 2020 |
Analgesic effect of S (+)-flurbiprofen plaster in a rat model of knee arthritis: analysis of gait and synovial fluid prostaglandin E
Topics: Analgesics; Animals; Arthritis, Experimental; Dinoprostone; Disease Models, Animal; Dose-Response Re | 2018 |
Effects of loxoprofen on the apical root resorption during orthodontic tooth movement in rats.
Topics: Animals; Biomarkers; Cytokines; Disease Models, Animal; Gene Expression Profiling; Immunohistochemis | 2018 |
Long-lasting breaches in the bladder epithelium lead to storage dysfunction with increase in bladder PGE2 levels in the rat.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cystitis, Interstitial; Dinoprostone; Disease Mode | 2008 |
High molecular weight hyaluronic acid relieved joint pain and prevented the progression of cartilage degeneration in a rabbit osteoarthritis model after onset of arthritis.
Topics: Adjuvants, Immunologic; Analgesics; Animals; Animals, Inbred Strains; Anti-Inflammatory Agents, Non- | 2010 |
Protective effect of lafutidine, a histamine H2 receptor antagonist, against loxoprofen-induced small intestinal lesions in rats.
Topics: 16,16-Dimethylprostaglandin E2; Acetamides; Ampicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer A | 2010 |
Effects of orally administered OP-1206 alpha-CD with loxoprofen-Na on walking dysfunction in the rat neuropathic intermittent claudication model.
Topics: Administration, Oral; alpha-Cyclodextrins; Alprostadil; Animals; Cyclodextrins; Disease Models, Anim | 2003 |